Initial experience with irreversible electroporation of liver tumours

Stillström, David; Beermann, Marie; Engstrand, Jennie; Freedman, Jacob; Nilsson, Henrik

doi:10.1016/j.ejro.2019.01.004

Cited by 26 publications

(17 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A small case series study reported that luminal narrowing was noted in in 27.7 % (15/55) of bile ducts within a 1-cm radius of the ablation defect [31]. The primary efficacy of IRE ranges from 66 to 100% for hepatic tumors in proximity to major vascular or biliary structures [30,[60][61][62][63][64]. The main limitation of IRE is that the ablation zone is created between two parallel electrodes spaced approximately 1-1.5 cm apart, which is relatively small compared to other techniques.…”

Section: Irreversible Electroporationmentioning

confidence: 99%

Image-Guided Ablation for Colorectal Liver Metastasis: Principles, Current Evidence, and the Path Forward

Lin

Paolucci

Brock

et al. 2021

Cancers

View full text Add to dashboard Cite

Image-guided ablation can provide effective local tumor control in selected patients with CLM. A randomized controlled trial suggested that radiofrequency ablation combined with systemic chemotherapy resulted in a survival benefit for patients with unresectable CLM, compared to systemic chemotherapy alone. For small tumors, ablation with adequate margins can be considered as an alternative to resection. The improvement of ablation technologies can allow the treatment of tumors close to major vascular structures or bile ducts, on which the applicability of thermal ablation modalities is challenging. Several factors affect the outcomes of ablation, including but not limited to tumor size, number, location, minimal ablation margin, RAS mutation status, prior hepatectomy, and extrahepatic disease. Further understanding of the impact of tumor biology and advanced imaging guidance on overall patient outcomes might help to tailor its application, and improve outcomes of image-guided ablation.

show abstract

Section: Irreversible Electroporationmentioning

confidence: 99%

Image-Guided Ablation for Colorectal Liver Metastasis: Principles, Current Evidence, and the Path Forward

Lin

Paolucci

Brock

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Tumor recurrence is possible following incomplete ablation in IRE [60][61][62]. In an analysis of 150 patients who received IRE for soft tissue tumors, 22 to 24% had disease recurrence [61].…”

Section: Discussionmentioning

confidence: 99%

Combinatorial effect of radium-223 and irreversible electroporation on prostate cancer bone metastasis in mice

Rojo

Perez

Damasco

et al. 2021

International Journal of Hyperthermia

View full text Add to dashboard Cite

Background: Metastatic prostate cancer in bone is difficult to treat as the tumor cells are relatively resistant to hormonal or chemotherapies when compared to primary prostate cancer. Irreversible electroporation (IRE) is a minimally invasive ablation procedure that has potential applications in the management of prostate cancer in bone. However, a common limitation of IRE is tumor recurrence, which arises from incomplete ablation that allows remaining cancer cells to proliferate. In this study, we combined IRE with radium-223 (Ra-223), a bone-seeking radionuclide that emits short track length alpha particles and thus is associated with reduced damage to the bone marrow and evaluated the impact of the combination treatment on bone-forming prostate cancer tumors. Methods: The antitumor activity of IRE and Ra-223 as single agents and in combination was tested in vitro against three bone morphogenetic protein 4 (BMP4)-expressing prostate cancer cell lines (C4-2B-BMP4, Myc-CaP-BMP4, and TRAMP-C2-BMP4). Similar evaluation was performed in vivo using a bone-forming C4-2B-BMP4 tumor model in nude mice. Results: IRE and Ra-223 as monotherapy inhibited prostate cancer cell proliferation in vitro, and their combination resulted in significant reduction in cell viability compared to monotherapy. In vivo evaluation revealed that IRE with single-dose administration of Ra-233, compared to IRE alone, reduced the rate of tumor recurrence by 40% following initial apparent complete ablation and decreased the rate of proliferation of incompletely ablated tumor as quantified in Ki-67 staining (53.58 ± 16.0% for IRE vs. 20.12 ± 1.63%; for IRE plus Ra-223; p ¼ 0.004). Histological analysis qualitatively showed the enhanced killing of tumor cells adjacent to bone by Ra-223 compared to those treated with IRE alone. Conclusion: IRE in combination with Ra-223, which enhanced the destruction of cancer cells that are adjacent to bone, resulted in reduction of tumor recurrence through improved clearance of proliferative cells in the tumor region.

show abstract

“…Numbers of emerging nano‐materials have been developed in computed tomography (CT), enhanced CT, positron emission tomography (PET) and magnetic resonance imaging (MRI) for HCC. [ 47–51 ] Additionally, the chemical substances with different attenuation coefficients acts as targeted CT‐imaging agents for accurate HCC diagnosis, which might be a promising reagent for achieving clinical efficient and safe HCC theranostics. [ 52 ] Song et al.…”

Section: Nanotechnology For Hcc Diagnosismentioning

confidence: 99%

Nanotechnology for Hepatocellular Carcinoma: From Surveillance, Diagnosis to Management

Wang

Liang

et al. 2021

Small

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) remains the fourth leading cause of cancer‐related death worldwide. However, the clinical diagnosis and treatment modalities are still relatively limited, which urgently require the development of new effective technologies. Recently, nanotechnology has gained extensive attention in HCC surveillance, imaging and pathological diagnosis, and therapeutic strategies. Typically, nanomedicines have been focused on early HCC diagnosis and precise treatment of advanced HCC, which has developed and improved a variety of new technologies and agents for future clinical practice. Furthermore, strategies of facilitating drug release and delivery in current treatment processes such as ablation, systematic therapy, transcatheter arterial chemoembolization, molecular targeted therapy, and immune‐modulating therapy have also been studied widely. This review summarizes the recent advances in this area according to current clinical HCC guidelines: 1) Nanoparticle‑based HCC surveillance; 2) Nanotechnology for HCC diagnosis; 3) Therapeutic advances for HCC Management; 4) Limitations of applications in nanotechnology for HCC; 5) Conclusions and perspectives. Although there are still many limitations and difficulties to overcome, the investigations of nanomedicines are believed to show potential applications in clinical practice.

show abstract

Initial experience with irreversible electroporation of liver tumours

Cited by 26 publications

References 29 publications

Image-Guided Ablation for Colorectal Liver Metastasis: Principles, Current Evidence, and the Path Forward

Image-Guided Ablation for Colorectal Liver Metastasis: Principles, Current Evidence, and the Path Forward

Combinatorial effect of radium-223 and irreversible electroporation on prostate cancer bone metastasis in mice

Nanotechnology for Hepatocellular Carcinoma: From Surveillance, Diagnosis to Management

Contact Info

Product

Resources

About